SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Syndax Pharmaceuticals Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$13.09+0.19 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
108M of 89M shares
Institutional holders
242
37 new, 39 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
0 buys · 9 sales
Net sold $2.75M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kynam Capital Management, LP | 8,520,000 | 9.98% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 6,744,049 | 7.80% | 13G (passive) amendment | Mar 31, 2025 |
| State Street Corporation | 5,658,465 | 6.40% | 13G (passive) | Jun 30, 2026 |
| The Goldman Sachs Group, Inc. | 5,581,828 | 6.50% | 13G (passive) amendment | Jun 30, 2025 |
| Goldman Sachs & Co. LLC | 4,510,669 | 5.20% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 4,457,143 | 5.05% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SNDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,020,006 | 10.10% | $197.18M | +765,580 | 0.00% |
| Kynam Capital Management, LP | 8,050,959 | 9.02% | $175.99M | – | 9.73% |
| Goldman Sachs Group Inc | 5,861,265 | 6.56% | $128.13M | +864,478 | 0.01% |
| State Street Corp | 5,658,424 | 6.34% | $123.69M | +1,228,348 | 0.00% |
| Bank Of America Corp /De/ | 4,045,094 | 4.53% | $88.43M | −204,742 | 0.01% |
| Vanguard Capital Management LLC | 3,927,892 | 4.40% | $85.86M | +105,313 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 3,779,900 | 4.23% | $82.63M | – | 0.86% |
| Eversept Partners, LP | 2,798,210 | 3.13% | $61.17M | −87,412 | 3.17% |
| Geode Capital Management, LLC | 2,584,136 | 2.89% | $56.50M | +427,078 | 0.00% |
| Hood River Capital Management LLC | 2,564,279 | 2.87% | $56.06M | +209,994 | 0.41% |
| Kingdon Capital Management, L.L.C. | 2,500,000 | 2.80% | $54.65M | – | 5.60% |
| Franklin Resources Inc | 2,286,499 | 2.56% | $49.98M | +136,420 | 0.01% |
| Millennium Management LLC | 2,053,960 | 2.30% | $44.90M | +1,854,436 | 0.02% |
| Vanguard Portfolio Management LLC | 1,921,796 | 2.15% | $42.01M | +184,655 | 0.00% |
| UBS Group AG | 1,893,750 | 2.12% | $41.40M | +740,088 | 0.01% |
| Elmind Capital, LP | 1,855,000 | 2.08% | $40.55M | – | 10.19% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,790,173 | 2.00% | $39.13M | +57,632 | 0.04% |
| Candriam S.C.A. | 1,696,040 | 1.90% | $37.04M | +770,708 | 0.17% |
| Soleus Capital Management, L.P. | 1,628,039 | 1.82% | $35.59M | −98,869 | 1.23% |
| Two Sigma Investments, LP | 1,578,125 | 1.77% | $34.50M | −1,471 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 242 | 108M | 100.0% | 37 / 96 | 77 / 39 | 18M | 10M |
| Q1 2026 | 247 | 101M | 100.0% | 45 / 99 | 68 / 25 | 20M | 13M |
| Q4 2025 | 230 | 100M | 100.0% | 34 / 82 | 81 / 28 | 15M | 17M |
| Q3 2025 | 228 | 101M | 100.0% | 42 / 82 | 71 / 28 | 16M | 17M |
| Q2 2025 | 216 | 102M | 100.0% | 31 / 85 | 67 / 32 | 18M | 17M |
| Q1 2025 | 218 | 101M | 100.0% | 32 / 90 | 60 / 26 | 23M | 20M |
| Q4 2024 | 215 | 98M | 100.0% | 36 / 88 | 61 / 29 | 29M | 20M |
| Q3 2024 | 210 | 90M | 100.0% | 39 / 85 | 59 / 24 | 18M | 9M |
| Q2 2024 | 196 | 88M | 99.0% | 26 / 88 | 58 / 18 | 11M | 17M |
| Q1 2024 | 189 | 95M | 100.0% | 30 / 81 | 55 / 18 | 11M | 8M |
| Q4 2023 | 177 | 92M | 100.0% | 36 / 82 | 43 / 34 | 34M | 15M |
| Q3 2023 | 175 | 73M | 81.3% | 20 / 76 | 59 / 11 | 11M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SNDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,528,047 | 3.95% | $77.12M | 0.72% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,823,912 | 3.16% | $61.73M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,315,500 | 2.59% | $50.62M | 0.06% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund | 1,211,108 | 1.36% | $26.47M | 0.40% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,013,559 | 1.14% | $22.16M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 971,932 | 1.09% | $18.52M | 0.05% | Jul 31, 2026 |
| Franklin Small Cap Growth Fund | 928,025 | 1.04% | $17.68M | 0.72% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 821,881 | 0.92% | $17.97M | 0.12% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 582,815 | 0.65% | $11.10M | 0.96% | Jul 31, 2026 |
| iShares Biotechnology ETF | 571,670 | 0.64% | $12.50M | 0.14% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 508,690 | 0.57% | $9.69M | 0.24% | Jul 31, 2026 |
| Loomis Sayles Small Cap Growth Fund | 499,843 | 0.56% | $10.93M | 0.48% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 449,122 | 0.50% | $8.80M | 0.02% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 442,134 | 0.50% | $8.66M | 0.05% | May 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 429,857 | 0.48% | $9.40M | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael A. Metzger | Chief Executive Officer, Director | 517,218 | 0.58% | Jul 9, 2026 |
| Nicholas A.J. Botwood | Head of R&D, CMO | 60,885 | 0.07% | Jun 12, 2026 |
| Keith A. Goldan | Chief Financial Officer | 139,252 | 0.16% | Jun 2, 2026 |
| Neil Gallagher | President, Head of R&D | 85,095 | 0.10% | Feb 12, 2025 |
| Aleksandra Rizo | Director | 49,000 | 0.05% | Feb 6, 2026 |
| Martin H. Huber Jr. | Director | 103,000 | 0.12% | Feb 6, 2026 |
| Dennis Podlesak | Director | 239,763 | 0.27% | Feb 6, 2026 |
| Pierre Legault | Director | 114,000 | 0.13% | Feb 6, 2026 |
| Keith Katkin | Director | 124,000 | 0.14% | Feb 6, 2026 |
| Jennifer Jarrett | Director | 114,000 | 0.13% | Feb 6, 2026 |
| William Meury | Director | 90,000 | 0.10% | Feb 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael A. Metzger Chief Executive Officer, Director | Jul 8, 2026 | Option exercise | +32,375 | $6.38 | $206.55K | 517,218 |
| Michael A. Metzger Chief Executive Officer, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −32,375 | $24.24 | $784.77K | 484,843 |
| Nicholas A.J. Botwood Head of R&D, CMO | Jun 12, 2026 | Sale(10b5-1 plan) | −31,235 | $18.14 | $566.60K | 60,885 |
| Nicholas A.J. Botwood Head of R&D, CMO | Jun 12, 2026 | Option exercise | +31,235 | $13.82 | $431.67K | 92,120 |
| Nicholas A.J. Botwood Head of R&D, CMO | Jun 11, 2026 | Sale(10b5-1 plan) | −34,280 | $18.00 | $617.04K | 60,885 |
| Nicholas A.J. Botwood Head of R&D, CMO | Jun 11, 2026 | Option exercise | +22,515 | $13.82 | $311.16K | 95,165 |
| Keith A. Goldan Chief Financial Officer | Jun 1, 2026 | Sale | −1,177 | $18.99 | $22.35K | 139,252 |
| Michael A. Metzger Chief Executive Officer, Director | Jun 1, 2026 | Sale | −6,847 | $18.99 | $130.02K | 484,843 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 9, 2026 | Sale | −17,159 | $21.03 | $360.85K | 491,690 |
| Keith A. Goldan Chief Financial Officer | Feb 9, 2026 | Sale | −3,410 | $21.03 | $71.71K | 140,429 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 6, 2026 | Sale | −7,412 | $20.62 | $152.84K | 508,849 |
| Keith A. Goldan Chief Financial Officer | Feb 6, 2026 | Sale | −2,082 | $20.62 | $42.93K | 143,839 |
| Keith Katkin Director | Feb 4, 2026 | Award | +24,000 | – | – | 124,000 |
| Dennis Podlesak Director | Feb 4, 2026 | Award | +48,000 | – | – | 239,763 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 4, 2026 | Award | +144,600 | – | – | 516,261 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 4, 2026 | Award | +73,000 | – | – | 371,661 |
| Nicholas A.J. Botwood Head of R&D, CMO | Feb 4, 2026 | Award | +24,000 | – | – | 59,165 |
| Nicholas A.J. Botwood Head of R&D, CMO | Feb 4, 2026 | Award | +36,000 | – | – | 95,165 |
| Jennifer Jarrett Director | Feb 4, 2026 | Award | +24,000 | – | – | 114,000 |
| Keith A. Goldan Chief Financial Officer | Feb 4, 2026 | Award | +21,500 | – | – | 115,171 |
| Keith A. Goldan Chief Financial Officer | Feb 4, 2026 | Award | +30,750 | – | – | 145,921 |
| Aleksandra Rizo Director | Feb 4, 2026 | Award | +24,000 | – | – | 49,000 |
| Pierre Legault Director | Feb 4, 2026 | Award | +24,000 | – | – | 114,000 |
| Martin H. Huber Jr. Director | Feb 4, 2026 | Award | +24,000 | – | – | 103,000 |
| Keith A. Goldan Chief Financial Officer | Jan 30, 2026 | Other | +1,219 | $8.48 | $10.34K | 93,671 |
| Keith A. Goldan Chief Financial Officer | Dec 1, 2025 | Gift | −1,224 | – | – | 92,452 |
| Michael A. Metzger Chief Executive Officer, Director | Sep 8, 2025 | Option exercise | +157,307 | $10.90 | $1.71M | 455,968 |
| Michael A. Metzger Chief Executive Officer, Director | Sep 8, 2025 | Sale(10b5-1 plan) | −157,307 | $16.41 | $2.58M | 298,661 |
| Dennis Podlesak Director | Aug 18, 2025 | Option exercise | +19,200 | $7.20 | $138.24K | 210,963 |
| Dennis Podlesak Director | Aug 18, 2025 | Sale(10b5-1 plan) | −19,200 | $15.84 | $304.13K | 191,763 |
| Dennis Podlesak Director | Aug 15, 2025 | Option exercise | +19,200 | $7.20 | $138.24K | 210,963 |
| Dennis Podlesak Director | Aug 15, 2025 | Sale(10b5-1 plan) | −19,200 | $15.54 | $298.37K | 191,763 |
| Dennis Podlesak Director | Aug 14, 2025 | Option exercise | +19,200 | $7.20 | $138.24K | 210,963 |
| Dennis Podlesak Director | Aug 14, 2025 | Sale(10b5-1 plan) | −19,200 | $14.19 | $272.45K | 191,763 |
| Keith A. Goldan Chief Financial Officer | Jul 31, 2025 | Other | +1,226 | $8.43 | $10.34K | 93,676 |
| Keith A. Goldan Chief Financial Officer | Jul 16, 2025 | Sale | −1,296 | $9.29 | $12.04K | 92,450 |
| Michael A. Metzger Chief Executive Officer, Director | Jul 16, 2025 | Sale | −7,534 | $9.29 | $69.99K | 298,661 |
| Keith Katkin Director | May 19, 2025 | Buy | +10,000 | $9.11 | $91.10K | 100,000 |
| Keith A. Goldan Chief Financial Officer | May 19, 2025 | Buy | +3,000 | – | – | 93,746 |
| Martin H. Huber Jr. Director | May 19, 2025 | Buy | +5,000 | $8.99 | $44.95K | 79,000 |
| Nicholas A.J. Botwood Head of R&D, CMO | May 16, 2025 | Buy | +11,765 | $9.00 | $105.89K | 35,165 |
| Michael A. Metzger Chief Executive Officer, Director | Mar 14, 2025 | Option exercise | +6,074 | $7.20 | $43.73K | 306,195 |
| Michael A. Metzger Chief Executive Officer, Director | Mar 4, 2025 | Option exercise | +7,814 | $7.20 | $56.26K | 307,935 |
| Michael A. Metzger Chief Executive Officer, Director | Mar 4, 2025 | Sale(10b5-1 plan) | −7,814 | $15.05 | $117.60K | 300,121 |
| Neil Gallagher President, Head of R&D | Feb 10, 2025 | Sale | −4,618 | $15.50 | $71.58K | 85,095 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 10, 2025 | Sale | −13,288 | $15.50 | $205.96K | 300,121 |
| Keith A. Goldan Chief Financial Officer | Feb 10, 2025 | Sale | −3,777 | $15.50 | $58.54K | 90,746 |
| Jennifer Jarrett Director | Feb 5, 2025 | Award | +25,000 | – | – | 90,000 |
| Pierre Legault Director | Feb 5, 2025 | Award | +25,000 | – | – | 90,000 |
| William Meury Director | Feb 5, 2025 | Award | +25,000 | – | – | 90,000 |
| Keith Katkin Director | Feb 5, 2025 | Award | +25,000 | – | – | 90,000 |
| Neil Gallagher President, Head of R&D | Feb 5, 2025 | Award | +18,500 | – | – | 66,313 |
| Neil Gallagher President, Head of R&D | Feb 5, 2025 | Award | +23,400 | – | – | 89,713 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 5, 2025 | Award | +60,500 | – | – | 224,409 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 5, 2025 | Award | +89,000 | – | – | 313,409 |
| Dennis Podlesak Director | Feb 5, 2025 | Award | +50,000 | – | – | 191,763 |
| Martin H. Huber Jr. Director | Feb 5, 2025 | Award | +25,000 | – | – | 74,000 |
| Aleksandra Rizo Director | Feb 5, 2025 | Award | +25,000 | – | – | 25,000 |
| Keith A. Goldan Chief Financial Officer | Feb 5, 2025 | Award | +23,400 | – | – | 94,523 |
| Keith A. Goldan Chief Financial Officer | Feb 5, 2025 | Award | +18,500 | – | – | 71,123 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Metzger Michael Director, Officer | Jul 8, 2026 | 32,375 | $752.40K | Jul 8, 2026 | Exercise of Stock Options |
| Nicholas A.J. Botwood Officer | Jun 12, 2026 | 31,235 | $566.69K | Jun 12, 2026 | Stock Option Exercise |
| Nicholas A.J. Botwood Officer | Jun 11, 2026 | 34,280 | $609.43K | Jun 11, 2026 | Open Market Purchase |
| Michael A. Metzger Officer, Director | Jun 1, 2026 | 6,847 | $130.03K | Jun 1, 2026 | Restricted Stock Vesting |
| Keith A. Goldan Officer | Jun 1, 2026 | 1,177 | $22.35K | Jun 1, 2026 | Restricted Stock Vesting |
| Michael A. Metzger Officer, Director | Feb 9, 2026 | 17,159 | $360.83K | Feb 9, 2026 | Restricted Stock Vesting |
| Keith A. Goldan Officer | Feb 9, 2026 | 3,410 | $71.71K | Feb 9, 2026 | Restricted Stock Vesting |
| Michael A. Metzger Officer, Director | Feb 6, 2026 | 7,412 | $152.84K | Feb 6, 2026 | Restricted Stock Vesting |
| Keith A. Goldan Officer | Feb 6, 2026 | 2,082 | $42.93K | Feb 6, 2026 | Restricted Stock Vesting |
| Metzger Michael Director, Officer | Sep 8, 2025 | 157,307 | $2.68M | Sep 8, 2025 | Exercise of Stock Options |
| G. Podlesak Dennis Director | Aug 18, 2025 | 14,400 | $226.66K | Aug 18, 2025 | Exercise of Stock Options |
| G. Podlesak Dennis Director | Aug 14, 2025 | 43,200 | $581.04K | Aug 14, 2025 | Exercise of Stock Options |
| Michael A. Metzger Officer, Director | Jul 16, 2025 | 7,534 | $69.96K | Jul 16, 2025 | Restricted Stock Vesting |
| Keith A. Goldan Officer | Jul 16, 2025 | 1,296 | $12.03K | Jul 16, 2025 | Restricted Stock Vesting |
| Neil Gallagher Officer | Jul 10, 2025 | 9,679 | $89.67K | Jul 10, 2025 | Restricted Stock Vesting |